Valneva Confirms Step Back From COVID-19 Vaccine Development
Ends Q2 On A Loss
Executive Summary
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
You may also be interested in...
Valneva Rebounds From 2022 Setbacks With Pivotal Success For Chikungunya Jab
The French firm’s vaccine candidate, VLA1553, has passed a Phase III milestone for the mosquito-borne disease – which has no approved options – as it bounces back from a year full of COVID-19-related disappointments.
Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO
Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback.
Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.